Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A

Autor: McDermott, D. F., Lee, J-L., Bjarnason, G. A., Larkin, J., Gafanov, R., Kochenderfer, M. D., Jensen, N. V., Donskov, F., Malik, J., Poprach, A., Tykodi, S. S., Alonso-Gordoa, T., Cho, D. C., Geertsen, P. F., Climent Duran, M. A., Di Simone, C., Liu, H., Burgents, J., Rodriguez-Lopez, K., Atkins, M. B.

Publikováno v: McDermott, D F, Lee, J-L, Bjarnason, G A, Larkin, J, Gafanov, R, Kochenderfer, M D, Jensen, N V, Donskov, F, Malik, J, Poprach, A, Tykodi, S S, Alonso-Gordoa, T, Cho, D C, Geertsen, P F, Climent Duran, M A, Di Simone, C, Liu, H, Burgents, J, Rodriguez-Lopez, K & Atkins, M B 2021, ' Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A ', Annals of Oncology, vol. 32, no. Suppl. 5, 666P, pp. S691-S692 . https://doi.org/10.1016/j.annonc.2021.08.062

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::fa77fe7a54818732b4b33019032a6fa2
https://portal.findresearcher.sdu.dk/da/publications/e7d6877e-1e6c-4db0-b3b7-b56ac5b3212c

Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population.

Autor: Millan B; Division of Urology, McMaster Institute of Urology, McMaster University, Hamilton, Ontario, Canada. Electronic address: braden.millan@medportal.ca., Breau RH; Division of Urology, University of Ottawa, Ottawa, Ontario, Canada., Mallick R; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada., Wood L; Division of Medical Oncology, QEII Health Sciences Center, Halifax, Nova Scotia, Canada., Rendon R; Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada., Finelli A; Division of Urology, University of Toronto, Toronto, Ontario, Canada., So AI; Department of Urologic Sciences, The University of British Columbia, Vancouver, British Columbia, Canada., Lavallée LT; Division of Urology, University of Ottawa, Ottawa, Ontario, Canada., Pouliot F; Division of Urology, CHU of Québec and Laval University, Montreal, Quebec, Canada., Bhindi B; Division of Urology, University of Calgary, Calgary, Alberta, Canada., Heng D; Division of Medical Oncology, University of Calgary, Calgary, Alberta, Canada., Drachenberg D; Division of Urology, University of Manitoba, Winnipeg, Manitoba, Canada., Tanguay S; Department of Surgery, McGill University, Montreal, Quebec, Canada., Dean L; Department of Surgery, Alberta Urology Institute Research Center, University of Alberta, Edmonton, Alberta, Canada., Basappa NS; Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta. Edmonton, Canada., Lattouf JB; Department of Surgery, University of Montreal, Montreal, Quebec, Canada., Bjarnason G; Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada., Lalani AK; Division of Medical Oncology, McMaster University, Hamilton, Ontario, Canada., Kapoor A; Division of Urology, McMaster Institute of Urology, McMaster University, Hamilton, Ontario, Canada.

Publikováno v: Urologic oncology [Urol Oncol] 2023 Jul; Vol. 41 (7), pp. 328.e15-328.e23. Date of Electronic Publication: 2023 May 16.

Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers.

Autor: Dragomir A; McGill University, Montreal, Canada. Electronic address: alice.dragomir@mcgill.ca., Nazha S; McGill University, Montreal, Canada., Tanguay S; McGill University, Montreal, Canada., Breau RH; The Ottawa Hospital, Ottawa, Canada., Bhindi B; Southern Alberta Institute of Urology, Alberta, Canada., Rendon RA; Queen Elizabeth II Health Sciences Centre, Halifax, Canada., Kapoor A; Juravinski Cancer Centre, McMaster University, Hamilton, Canada., Hotte SJ; Juravinski Cancer Centre, McMaster University, Hamilton, Canada., Basappa N; Cross Cancer Institute, University of Alberta, Edmonton, Canada., Fairey A; Cross Cancer Institute, University of Alberta, Edmonton, Canada., So AI; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, Canada., Kollmannsberger C; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, Canada., Finelli A; Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada., Hansen A; Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada., Canil C; The Ottawa Hospital, Ottawa, Canada., Heng D; Tom Baker Cancer Centre, University of Calgary, Calgary, Canada., Lattouf JB; Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, Canada., Bjarnason G; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada., Power N; Western University, London, Canada., Pouliot F; Centre Hospitalier Universitaire de Québec, University of Laval, Quebec, Canada., Wood LA; Queen Elizabeth II Health Sciences Centre, Halifax, Canada.

Publikováno v: European urology focus [Eur Urol Focus] 2022 Nov; Vol. 8 (6), pp. 1703-1710. Date of Electronic Publication: 2021 Nov 01.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance).

Autor: Patel JN; Department of Cancer Pharmacology and Pharmacogenomics, Levine Cancer Institute, Atrium Health, Charlotte., Jiang C; Alliance Statistics and Data Center., Owzar K; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina., Mulkey F; Alliance Statistics and Data Center., Luzum JA; Department of Clinical Pharmacy, University of Michigan, Ann Arbor, Michigan., Mamon HJ; Department of Radiation Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts., Haller DG; Department of Gastrointestinal Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Dragovich T; Department of Hematology/Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona., Alberts SR; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., Bjarnason G; Department of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada., Willet CG; Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina., Niedzwiecki D; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina., Enzinger P; Department of Radiation Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts., Ratain MJ; Center for Personalized Therapeutics, University of Chicago, Chicago, Illinois., Fuchs C; Department of Medical Oncology, Smilow Cancer Hospital, Yale University, New Haven, Connecticut., McLeod HL; Department of Precision Medicine, USF Taneja College of Pharmacy and the Geriatric Oncology Consortium, Tampa, Florida, USA.

Publikováno v: Pharmacogenetics and genomics [Pharmacogenet Genomics] 2021 Dec 01; Vol. 31 (9), pp. 215-220.